Maravai Lifesciences Holdings Inc 's Cash & cash equivalent grew by 4.18 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Maravai Lifesciences Holdings Inc 's Quick Ratio to 2.14, Quick Ratio remained below Maravai Lifesciences Holdings Inc average.

Within Major Pharmaceutical Preparations industry 298 other companies have achieved higher Quick Ratio than Maravai Lifesciences Holdings Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 758 to 1490.

Explain Quick Ratio?
How much Cash & cash equivalents MRVI�s has?
What are MRVI�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MRVI/financial-strength

https://api.csimarket.com/api/v1/companies/MRVI/fundamentals

https://api.csimarket.com/api/v1/companies/MRVI/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

MRVI Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-44.52 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-70.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.14	Subscribe	Subscribe	Subscribe	Subscribe
MRVI's Total Ranking	# 1490	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-13.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.18 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 299
Healthcare Sector	# 521
Overall Market	# 1490

Quick Ratio Statistics
High	Average	Low
11.5	5.48	0.78
(Sep 30 2021)		(Sep 30 2023)

Financial Statements
Maravai Lifesciences Holdings Inc 's Current Liabilities	$ 34 Millions	Visit MRVI's Balance sheet
Maravai Lifesciences Holdings Inc 's Cash & cash equivalent	$ 73 Millions	Visit MRVI's Balance sheet
Source of MRVI's Sales		Visit MRVI's Sales by Geography

Cumulative Maravai Lifesciences Holdings Inc 's Quick Ratio

MRVI's Quick Ratio for the trailling 12 Months

MRVI Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-36.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-53.08 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	3.24	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3668	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-14.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-24.49 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to MRVI Financial Strength Comparisons >> Go to Compare MRVI Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MRVI's Current Liabilities to $34.16 millions, cumulative Quick Ratio to 3.24 below the MRVI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Maravai Lifesciences Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3598 to 3668.

Explain Quick Ratio?
How much Cash & cash equivalents MRVI�s has?
What are MRVI�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 427
Healthcare Sector	# 869
Within the Market	# 3668

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.22	4.36	1.4
(Sep 30 2024)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions
United Therapeutics Corporation	5.51	$ 3,439.800 Millions	$ 624.300 Millions
Immuneering Corporation	5.45	$ 58.776 Millions	$ 10.791 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Cellectar Biosciences Inc	4.24	$ 24.582 Millions	$ 5.798 Millions
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Calcimedica Inc	4.12	$ 13.768 Millions	$ 3.339 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Xilio Therapeutics Inc	3.47	$ 122.182 Millions	$ 35.258 Millions
Corbus Pharmaceuticals Holdings Inc	3.30	$ 115.337 Millions	$ 34.967 Millions
Maia Biotechnology Inc	3.30	$ 21.339 Millions	$ 6.474 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions

Date modified: 2026-11-07T13:25:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.